4.4 Article

The Influence of Depressive Symptoms on Quality of Life after Stroke: A Prospective Study

Journal

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
Volume 24, Issue 1, Pages 201-209

Publisher

ELSEVIER
DOI: 10.1016/j.jstrokecerebrovasdis.2014.08.020

Keywords

Stroke; depression; quality of life; prospective study

Ask authors/readers for more resources

Background: Poststroke depressive symptoms have prospectively predicted impairment of health-related quality of life (HRQOL). However, it is not known whether such predictive effect is independent of HRQOL at 1 month after stroke. This study aimed to investigate the impact of depressive symptoms at 1 and 3 months after stroke on the 3-month poststroke HRQOL and to investigate the influence of the HRQOL measured at 1 month after stroke on these relationships. Methods: We prospectively evaluated 67 patients at 1 and 3 months after a first-ever ischemic stroke from 106 eligible patients who have been consecutively admitted to the neurology ward of a teaching hospital. A psychiatrist assessed the presence of depressive symptoms using the 31-item version of the Hamilton Rating Scale for Depression and the HRQOL was assessed with the 36-item Short-Form Health Survey from the Medical Outcomes Study. We used linear regression to measure the impact of depressive symptoms, HRQOL at 1 month, and potential confounders on HRQOL at 3 months. Results: We found an association between depressive symptoms at 1 month and HRQOL at 3 months after the stroke; however, this association was not significant when adjusting for the 1 month poststroke HRQOL. Depressive symptoms at 3 months were associated with HRQOL at 3 months after stroke, independently of the poststroke HRQOL at 1 month and potential confounders. Conclusions: Current depressive symptoms at 3 months are important for HRQOL at 3 months after stroke; however, regarding the prospective prediction, HRQOL at 1 month is the most relevant factor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes

Ole Kohler-Forsberg, Louisa G. Sylvia, Michael Thase, Joseph R. Calabrese, Mauricio Tohen, Charles L. Bowden, Melvin McInnis, Dan Iosifescu, James H. Kocsis, Edward S. Friedman, Terence A. Ketter, Susan L. McElroy, Richard C. Shelton, Vicki Fung, Michael J. Ostacher, Andrew A. Nierenberg

Summary: This study found that patients with bipolar disorder who used lithium in combination with antipsychotics or anticonvulsants showed worse response compared to those who only used lithium. However, compared to lithium and anticonvulsants, the combined use of lithium and antipsychotics showed slight improvement in general and manic symptoms, but worse development in glucose, triglycerides, and metabolic syndrome.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Neurosciences

Relationships between interoceptive sensibility and resting-state functional connectivity of the insula in obsessive-compulsive disorder

Goi Khia Eng, Katherine A. Collins, Carina Brown, Molly Ludlow, Russell H. Tobe, Dan Iosifescu, Emily R. Stern

Summary: Patients with OCD exhibit abnormality in their internal sensation perception and altered functioning of the insula, and these differences are associated with the connectivity of the insula. The study found that OCD patients showed a three-component solution in their interoceptive sensibility, compared to the two-component solution in controls. Furthermore, the study identified specific network connections in the insula that could be targeted for modulation of interoceptive sensibility in OCD.

CEREBRAL CORTEX (2022)

Article Clinical Neurology

Affective and somatic symptom clusters in depression and their relationship to treatment outcomes in the STAR*D sample

Katherine A. Collins, Goi Khia Eng, Umit Tural, Molly K. Irvin, Dan Iosifescu, Emily R. Stern

Summary: This study used a large dataset to explore the heterogeneity of depression symptoms and identified different symptom subsets and patient groups. By comparing the response to citalopram in different groups, it was found that somatic symptoms and core affective symptoms had different impacts on treatment. This highlights the importance of assessing a wide range of symptoms and the need for treatments specifically targeting physical symptoms in exploring the heterogeneity of depression.

JOURNAL OF AFFECTIVE DISORDERS (2022)

Article Clinical Neurology

Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response

Maya Kuperberg, Ole Kohler-Forsberg, Alec P. Shannon, Nevita George, Sophie Greenebaum, Charles L. Bowden, Joseph R. Calabrese, Michael Thase, Richard C. Shelton, Melvin McInnis, Thilo Deckersbach, Mauricio Tohen, James H. Kocsis, Terence A. Ketter, Edward S. Friedman, Dan Iosifescu, Michael J. Ostacher, Louisa G. Sylvia, Susan L. McElroy, Andrew A. Nierenberg

Summary: The study found that patients with bipolar disorder have an increased cardiometabolic risk associated with symptom severity, and treatment with quetiapine can worsen cardiometabolic markers. The results highlight the importance of monitoring cardiometabolic risks during treatment.

JOURNAL OF AFFECTIVE DISORDERS (2022)

Review Psychology, Clinical

Adiponectin in anorexia nervosa and its modifiers: A meta-regression study

Umit Tural, Dan Iosifescu

Summary: Adiponectin levels are higher in overall AN and specifically in the binge-eating/purging and the restrictive AN subtypes. Insulin, IGF-1, BMI, triglyceride, resistin, glucose, and IL-6 levels are significant modifiers of adiponectin levels.

INTERNATIONAL JOURNAL OF EATING DISORDERS (2022)

Review Multidisciplinary Sciences

Guidelines' recommendations for the treatment-resistant depression: A systematic review of their quality

Franciele Cordeiro Gabriel, Airton Tetelbom Stein, Daniela de Oliveira Melo, Gessica Caroline Henrique Fontes-Mota, Itamires Benicio dos Santos, Camila da Silva Rodrigues, Andrea D. Dourado, Monica Cristiane Rodrigues, Renerio Fraguas, Ivan Florez, Diogo Telles Correia, Eliane Ribeiro

Summary: Depression is a serious mental health disorder, and some patients with depression fail to respond to antidepressant treatment, known as treatment-resistant depression (TRD). Clinical practice guidelines (CPGs) aim to improve diagnosis and treatment, but there is significant variability in the definitions and recommendations for TRD among high-quality CPGs.

PLOS ONE (2023)

Review Clinical Neurology

Combinations of dextromethorphan for the treatment of mood disorders-a review of the evidence

Zamfira Parincu, Dan V. Iosifescu

Summary: Major depressive disorder is a leading cause of disability globally. Current pharmacotherapies targeting monoamine receptors are often ineffective and slow-acting, highlighting a need for more rapid and effective treatments. Studies have shown that combining dextromethorphan with quinidine or bupropion can effectively reduce depressive symptoms in MDD, but results are mixed for TRD and bipolar depression, warranting further research.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2023)

Letter Psychiatry

Suicidal ideation and behavior in schizophrenia: The role of negative urgency and psychiatric symptoms

Matthew J. Hoptman, Umit Tural, Molly S. Arnold, Katherine A. Collins, Kathryn T. Evans, Molly K. Irvin, Zamfira Parincu, Danielle N. Rette, Allison M. Sparpana, Elizabeth F. Sullivan, Dan V. Iosifescu

SCHIZOPHRENIA RESEARCH (2023)

Review Medicine, General & Internal

Factors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review

Franciele Cordeiro Gabriel, Daniela Oliveira de Melo, Airton Tetelbom Stein, Gessica Caroline Henrique Fontes-Mota, Itamires Benicio dos Santos, Camila da Silva Rodrigues, Monica Cristiane Rodrigues, Tatiane Bomfim Ribeiro, Renerio Fraguas, Ivan D. Florez, Diogo Telles-Correia, Eliane Ribeiro

Summary: This study aimed to assess the quality of clinical practice guidelines for the pharmacological treatment of depression and explore factors associated with higher quality. The results showed that 27% of the guidelines were classified as high quality, with 11.1% having high-quality recommendations. Factors associated with higher quality included handling of conflicts of interest, multiprofessional teams, and type of institution.

BMJ OPEN (2023)

Review Biology

Comparison of Adiponectin Levels in Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Obesity, Constitutional Thinness, and Healthy Controls: A Network Meta-Analysis

Umit Tural, Allison Sparpana, Elizabeth Sullivan, Dan V. Iosifescu

Summary: This study conducted a network meta-analysis to investigate the differences in adiponectin levels across eating disorders, obesity, constitutional thinness, and healthy controls. The results showed that participants with anorexia nervosa had significantly higher adiponectin levels, while obesity and binge-eating disorder were associated with significantly lower levels. These findings suggest that adiponectin may be an important marker of metabolic imbalance.

LIFE-BASEL (2023)

Article Psychiatry

Photobiomodulation An Emerging Treatment Modality for Depression

Willians Fernando Vieira, Dan Iosifescu, Kayla Marie McEachern, Maia Gersten, Paolo Cassano

PSYCHIATRIC CLINICS OF NORTH AMERICA (2023)

Article Health Care Sciences & Services

Protocol Report on the Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) Study

Dan V. Iosifescu, Xiaotong Song, Maia B. Gersten, Arwa Adib, Yoonju Cho, Katherine M. Collins, Kathy F. Yates, Aura M. Hurtado-Puerto, Kayla M. McEachern, Ricardo S. Osorio, Paolo Cassano

Summary: This study aims to investigate the impact, safety, and mechanisms of transcranial photobiomodulation (t-PBM) on cognition in patients with amnestic mild cognitive impairment (aMCI) and early Alzheimer's disease (AD). The participants will receive 24 sessions of t-PBM treatment over 8 weeks, and the study will explore whether baseline tau burden and changes in mitochondrial function moderate the cognitive changes observed after t-PBM therapy. Additionally, changes in the fMRI blood-oxygenation-level-dependent (BOLD) signal after a single treatment will be examined to demonstrate t-PBM-dependent increases in prefrontal cortex blood flow.

HEALTHCARE (2023)

Article Medicine, General & Internal

The relationship of major depressive disorder with Crohn?s disease activity

Carolina Bortolozzo Graciolli Facanali, Carlos Walter Sobrado Junior, Renerio Fraguas Junior, Marcio Roberto Facanali Junior, Lucas Rodrigues Boarini, Lucas Faraco Sobrado, Ivan Cecconello

Summary: This study aims to assess the prevalence of major depressive disorder (MDD) in patients with Crohn's disease (CD) and examine the relationship between MDD and CD outcomes. The findings showed a high prevalence of MDD in CD patients and suggested a potential association between MDD and CD activity.

CLINICS (2023)

Article Psychiatry

Personality characteristics, not clinical symptoms, are associated with anhedonia in a community sample: A preliminary investigation

Russell H. Tobe, Lucia Tu, John R. Keefe, Melissa M. Breland, Benjamin A. Ely, Melissa Sital, Jasmin T. Richard, Umit Tural, Dan V. Iosifescu, Vilma Gabbay

Summary: This study aims to examine the factors influencing the expression of anhedonia. By evaluating physical, developmental, and clinical measures, the study found a correlation between personality traits and anhedonia, while diagnostic and symptom measures were not significant predictors of anhedonia.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Meeting Abstract Neurosciences

Dose Dependent Effects of Transcranial Photobiomodulation on Brain Temperature in Major Depression

Akila Weerasekera, Eva Ratai, Jacek Dmochowski, Katherine A. Collins, Aura M. Hurtado, Luis De Taboada, Maia B. Gersten, Julie A. Clancy, Matthew J. Hoptman, Molly K. Irvin, Allison Sparpana, Elizabeth Sullivan, Xiaotong Song, Arwa Adib, Paolo Cassano, Dan V. Iosifescu

NEUROPSYCHOPHARMACOLOGY (2022)

No Data Available